Clinical trialRSS4 days ago
A company called Allrock Bio is testing a new oral medication called ROC-101 for pulmonary hypertension (a condition where blood pressure in the lungs becomes dangerously high). This is a Phase 2a trial, which means they're checking if the drug is safe and works well as an add-on treatment. The trial is now enrolling patients across the U.S., Canada, and Europe.
WHY IT MATTERSIf ROC-101 proves effective as an add-on therapy, it could offer pulmonary hypertension patients a new oral option to combine with their existing treatments, potentially improving symptom control.
Clinical trialCLINICALTRIALSApr 3
Doctors across Europe are building a database to track rare head and neck cancers like nasopharynx cancer and salivary gland cancer. They're recruiting 13,600 patients to help them understand how these cancers develop and improve treatment. This registry will help researchers learn more about these uncommon cancers so doctors can treat patients better in the future.
WHY IT MATTERSIf you have a rare head and neck cancer like nasopharynx or salivary gland cancer, joining this registry helps European specialists understand your condition better and could improve treatment options for patients like you.
ResearchPUBMEDApr 1
Researchers in Italy tested a new way to diagnose rare genetic diseases in children using whole genome sequencing—a test that reads all of a person's genetic code. Between 2018 and 2022, they studied 64 children with complex neurological problems that doctors couldn't figure out. This study shows whether this genetic test could help find answers faster for kids with mysterious rare diseases.
WHY IT MATTERSIf your child has unexplained neurological symptoms and multiple doctors haven't found a diagnosis, this research demonstrates that whole genome sequencing through healthcare systems may finally provide answers—potentially ending years of diagnostic uncertainty.
PolicyPUBMEDApr 1
A European network for rare connective tissue diseases has created a new model where patients are treated as equal partners in research and care decisions. Instead of doctors alone deciding what to study and how to treat patients, this network includes patients in every step—from identifying problems to writing research papers together. This approach helps address long diagnostic delays and gaps in care that patients with these rare diseases often face.
WHY IT MATTERSPatients with rare connective tissue diseases can now directly influence research priorities and treatment approaches through structured partnership roles, rather than having decisions made without their input.
Clinical trialCLINICALTRIALSMar 27
Researchers in France are recruiting 5,000 newborns to test a new way of screening for rare diseases using genome sequencing—a complete reading of a baby's DNA. Instead of the current blood spot tests that check for only a few dozen conditions, this study will see if reading a baby's entire genome can safely and effectively find many more rare genetic diseases at birth. This is one of the first major studies in Europe to test this approach.
WHY IT MATTERSThis trial could expand newborn screening in France to detect dozens of additional rare genetic diseases at birth, potentially allowing earlier treatment and better health outcomes for babies with conditions that currently go undiagnosed until symptoms appear.
PolicyPUBMEDMar 26
European countries are updating their rules for deciding whether new medicines work well and are worth the cost, especially for rare diseases and children. Because rare diseases affect few people and there's less testing data available, countries are making special adjustments to their evaluation methods. This study looked at how 28 European countries and the UK are handling these evaluations differently.
WHY IT MATTERSIf your country updates its health technology assessment rules, it could affect how quickly new rare disease treatments get approved and whether your insurance will cover them.
ResearchPUBMEDMar 26
Scientists studied a large group of patients in Europe with rare diseases caused by problems in mitochondrial aminoacyl-tRNA synthetases—proteins that help mitochondria (the energy centers of cells) make other proteins. They found 38 patients with 63 different genetic changes and created a method to match patients' symptoms with similar cases in medical literature, which helps doctors figure out what disease a patient actually has.
WHY IT MATTERSIf you or your child has unexplained seizures, developmental delays, or neurological symptoms, this research provides doctors with a new tool to identify whether mitochondrial aminoacyl-tRNA synthetase variants are the cause—potentially leading to a diagnosis after years of testing.
ResearchPUBMEDMar 26
Researchers studied how medicines for rare diseases are developed by non-industry groups like universities and charities, compared to pharmaceutical companies. Between 2000 and 2022, only about 7% of rare disease medicine projects came from these non-industry organizations. While these groups got help from regulators at similar rates as companies, very few of their medicines actually made it to patients—only six succeeded, and all had to partner with pharmaceutical companies to finish the job.
WHY IT MATTERSThis research shows that academic and charity-led rare disease drug projects face significant barriers to reaching patients, suggesting that funding and regulatory support for non-industry developers could unlock more treatment options for rare diseases that pharmaceutical companies might overlook.
Clinical trialCLINICALTRIALSMar 26
Researchers across 7 European countries are working together to develop better ways to diagnose two rare kidney diseases: atypical hemolytic-uremic syndrome (aHUS) and C3 glomerulonephritis (C3G). This study is enrolling 180 people, including patients with these conditions and healthy volunteers, to test new diagnostic tools that could help doctors identify these diseases more quickly and accurately.
WHY IT MATTERSThis trial is developing improved diagnostic tests for aHUS and C3G, which could help patients get diagnosed faster and start treatment sooner—critical since these complement-mediated kidney diseases can cause permanent kidney damage if left untreated.